Pomalidomide-7-NH2
98%
- Product Code: 121638
CAS:
497146-96-0
| Molecular Weight: | 288.26 g./mol | Molecular Formula: | C₁₃H₁₂N₄O₄ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8°C |
Product Description:
Pomalidomide-7-NH2 is primarily utilized in the field of medicinal chemistry and pharmaceutical research. It serves as a key intermediate in the synthesis of pomalidomide derivatives, which are investigated for their potential therapeutic applications. This compound is particularly significant in the development of drugs targeting multiple myeloma and other hematologic malignancies. Researchers explore its efficacy in modulating the immune system and inducing apoptosis in cancer cells. Additionally, it is studied for its role in enhancing the activity of cereblon, a protein involved in the degradation of specific disease-causing proteins. Its applications extend to preclinical studies aimed at optimizing drug formulations and improving treatment outcomes for patients with refractory cancers.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | $691.27 |
+
-
|
| 0.005 | 10-20 days | $1,987.40 |
+
-
|
Pomalidomide-7-NH2
Pomalidomide-7-NH2 is primarily utilized in the field of medicinal chemistry and pharmaceutical research. It serves as a key intermediate in the synthesis of pomalidomide derivatives, which are investigated for their potential therapeutic applications. This compound is particularly significant in the development of drugs targeting multiple myeloma and other hematologic malignancies. Researchers explore its efficacy in modulating the immune system and inducing apoptosis in cancer cells. Additionally, it is studied for its role in enhancing the activity of cereblon, a protein involved in the degradation of specific disease-causing proteins. Its applications extend to preclinical studies aimed at optimizing drug formulations and improving treatment outcomes for patients with refractory cancers.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :